within Pharmacolibrary.Drugs.ATC.A;

model A16AB05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.04833333333333333,
    adminDuration  = 600,
    adminMass      = 0.1,
    adminCount     = 1,
    Vd             = 0.00020999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Laronidase is a recombinant human alpha-L-iduronidase, an enzyme replacement therapy approved for the treatment of mucopolysaccharidosis I (MPS I, Hurler, Hurler-Scheie, and Scheie syndromes), a rare lysosomal storage disorder. Laronidase helps reduce non-neurological symptoms related to glycosaminoglycan accumulation in affected individuals. It is currently approved and used for MPS I treatment.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in pediatric and adult patients with MPS I (non-neurological). Study population: 8 children (aged 5–12 years), 8 adults (aged 15–43 years).</p><h4>References</h4><ol><li>,Laronidase.,BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,2002<a href='https://pubmed.ncbi.nlm.nih.gov/12196045/'>https://pubmed.ncbi.nlm.nih.gov/12196045/</a></li><li>Ed J Wraith, John J Hopwood, Maria Fuller, Peter J Meikle, Doug A Brooks,Laronidase treatment of mucopolysaccharidosis I.,BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy,2005<a href='https://pubmed.ncbi.nlm.nih.gov/15691212/'>https://pubmed.ncbi.nlm.nih.gov/15691212/</a></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end A16AB05;
